SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

1 year ago

JERSEY CITY, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to…

Korro to Participate in Upcoming September Investor and Scientific Conferences

1 year ago

CAMBRIDGE, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing…

Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

1 year ago

PDUFA target action date set for December 27, 2024 FDA currently plans to hold an Advisory Committee meeting REDWOOD CITY,…

Spectral AI Completes Burn Center Enrollment for U.S. Burn Pivotal Study

1 year ago

Milestone Achievement Advances Commercialization Timeline for DeepView™ System for Burn IndicationDALLAS, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc.…

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

1 year ago

ORX142 is currently in IND enabling activities for select neurological, neurodegenerative, and psychiatric disorders with excessive daytime sleepiness (EDS)BOSTON and…

CAMP4 Therapeutics Secures Rare Pediatric Disease Designation for CMP-CPS-001 for the Treatment of Urea Cycle Disorders

1 year ago

CAMBRIDGE, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics, a clinical-stage biotechnology company developing a pipeline of RNA-based therapeutics…

Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2024 and Business Update

1 year ago

Exploration and evaluation of strategic alternatives continueWESTPORT, Conn., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the…

Humacyte Presents Positive Long-Term Results of ATEV™ in Treatment of Vascular Trauma in Military Setting from Ukraine Humanitarian Program

1 year ago

- Results presented at the Department of Defense’s Military Health System Research Symposium (MHSRS) - - In real-world military setting…

BetterLife Highlights Advantages of Non-hallucinogenic LSD Derivative BETR-001 and Publication of its Methods to Treat Mood Disorders Patent

1 year ago

VANCOUVER, British Columbia, Aug. 27, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF…

Rezolute to Participate in Upcoming Investor Conferences

1 year ago

REDWOOD CITY, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease…